Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Le Bao, Ying Liu, Long Chen, Fei Wang, Yuzhi Zhu, Shuang Liang, Youbin Wang, Hetai Quan, Pengfei Li
BACKGROUND: Acute cerebral infarction profoundly affects patients' neurological function and quality of life. This study explores the impact of Solitaire AB stent thrombectomy, combined with tirofiban and butylphthalide, on neurological function and inflammatory factors in patients with acute cerebral infarction. METHODS: Seventy-three eligible patients treated between 2021 and 2023 were divided into a control group (Solitaire AB stent thrombectomy) and a treatment group (Solitaire AB stent thrombectomy with tirofiban and butylphthalide)...
February 29, 2024: International Journal of Neuroscience
#22
JOURNAL ARTICLE
Haajeera Samsudeen, V P Dharani Shrinivasan
BACKGROUND: Myocardial infarction (MI) is a leading cause of death worldwide, particularly in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, has shown promise as adjunctive therapy in the emergency management of MI in diabetic patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in this patient population is necessary to optimize treatment strategies and improve patient outcomes. METHODOLOGY: This review article utilized a systematic approach to gather relevant research articles, clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients...
January 25, 2024: Current Diabetes Reviews
#23
JOURNAL ARTICLE
Liang Chen, Ming-Xin Gao, Xin Du, Chi Wang, Wen-Yuan Yu, Hong-Li Liu, Xiao-Hang Ding, Bo-Lin Wang, Kui Zhang, Dong Xu, Zhen Han, Bao-Dong Xie, Ran Dong, Yang Yu
BACKGROUND: For complete revascularization, patients with diffuse coronary artery disease should have a coronary endarterectomy and a coronary artery bypass graft (CE-CABG). Sadly, CE can lead to a lack of endothelium, which raises the risk of thrombotic events. Even though daily dual antiplatelet therapies (DAPT) have been shown to reduce thrombotic events, the risk of perioperative thrombotic events is high during the high-risk period after CE-CABG, and there is no consistent protocol to bridge DAPT...
January 15, 2024: Trials
#24
JOURNAL ARTICLE
Yuxia Mi, Zhigang Hou, Jiaqi Liu, Caixia Zhang
OBJECTIVE: To explore the clinical efficacy and safety of edaravone dexborneol combined with tirofiban in the treatment of acute cerebral infarction. METHODS: This is a retrospective study. A total of 80 patients with acute cerebral infarction (ACI) treated in Cangzhou People's Hospital from March 2018 to December 2021 were selected, and randomly divided into the routine group(n=40) and intervention group(n=40) according to the principle of random draw. Neurological deficits in the two groups were evaluated and compared before and after treatment using the National Institutes of Health Stroke Scale (NIHSS)...
2024: Pakistan Journal of Medical Sciences Quarterly
#25
JOURNAL ARTICLE
Zhen-Ni Guo, Ke-Jia Zhang, Peng Zhang, Yang Qu, Reziya Abuduxukuer, Thanh N Nguyen, Hui-Sheng Chen, Yi Yang
BACKGROUND: Nearly half of patients with acute ischemic stroke who undergo intravenous thrombolysis (IVT) fail to achieve excellent functional outcomes. Early administration of tirofiban after IVT may improve patient outcomes. OBJECTIVE: To evaluate the efficacy and safety of early tirofiban administration after intravenous tenecteplase in patients with acute ischemic stroke. METHODS AND DESIGN: The ADVENT trial is a multicenter, randomized, parallel-controlled, double-blind clinical trial...
January 9, 2024: European Stroke Journal
#26
JOURNAL ARTICLE
Elena Zapata-Arriaza, Manuel Medina-Rodríguez, Francisco Moniche Álvarez, Asier de Albóniga-Chindurza, Marta Aguilar-Pérez, Leire Ainz-Gómez, Pablo Baena-Palomino, Aynara Zamora, Blanca Pardo-Galiana, Fernando Delgado-Acosta, Roberto Valverde Moyano, Elvira Jiménez-Gómez, Isabel Bravo Rey, Rafael Oteros Fernández, Irene Escudero-Martínez, Isabel Vielba-Gomez, Lluis Morales Caba, Jose Díaz Pérez, Estefania García Molina, Sonia Mosteiro, María Del Mar Castellanos Rodrigo, Laura Amaya Pascasio, Carlos Hidalgo, María Del Mar Freijo Guerrero, Eva González Díaz, Jose María Ramírez Moreno, Luis Fernández Prudencio, Mikel Terceño Izaga, Saima Bashir Viturro, Miguel Ángel Gamero-García, Silvia Jiménez Jorge, Clara Rosso Fernández, Joan Montaner, Alejandro González García
RATIONALE: In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients to avoid in-stent reocclusion is yet to be elucidated. AIMS: To assess efficacy and safety of intravenous tirofiban versus intravenous aspirin in patients undergoing MT plus carotid stenting in the setting of AIS due to TL. SAMPLE SIZE ESTIMATES: Two hundred forty patients will be enrolled, 120 in every treatment arm...
January 9, 2024: Trials
#27
EDITORIAL
Bonaventure Ip, Hao Wang, Simon Chun Ho Yu
No abstract text is available yet for this article.
February 2024: Cardiovascular and Interventional Radiology
#28
JOURNAL ARTICLE
Jie Dou, Jie Gao, Huihui Yang, Ruoling Guo, Chao Jiang, Jingtao Guo, Donglei Luo
This study investigated the efficacy and safety of pharmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP) during hospitalization for patients with ST-segment elevation myocardial infarction (STEMI) to provide references for the treatment of STEMI. Patients with STEMI who fulfilled the inclusion and exclusion criteria and attended Chengde Central Hospital, Hebei Province, China, between September 3, 2019, and December 28, 2021, were included in this study. The experimental group received PHDP and the control group underwent primary percutaneous coronary intervention (PPCI)...
2024: Clinical and Applied Thrombosis/hemostasis
#29
JOURNAL ARTICLE
Chang Liu, Fengli Li, Liyuan Chen, Jiacheng Huang, Hongfei Sang, Thanh N Nguyen, Jeffrey L Saver, Mohamad Abdalkader, Weiling Kong, Jie Yang, Changwei Guo, Chen Gong, Liping Huang, Yanzhu Pan, Xinxin Wang, Yangmei Chen, Zhongming Qiu, Wenjie Zi
OBJECTIVE: Renal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban. Hence, this study aimed to investigate the roles of renal function in determining efficacy and safety of intravenous tirofiban before endovascular treatment (EVT) for acute ischemic stroke patients with large vessel occlusion (LVO). METHODS: This study was a post hoc exploratory analysis of the RESCUE-BT trial...
December 29, 2023: Annals of Clinical and Translational Neurology
#30
REVIEW
Naziha Hasan, Walter Jauregui, Mahrukh Zubair, Venugopala K Pushparajan, Bryan J Carson, Durga Manaswini Attaluri, Diny Dixon, Aman Jaisinghani, Andres Chuecos, Deepika Ravichandran
ST-Elevation Myocardial Infarction and non-ST Elevation Myocardial Infarction belong to the acute coronary syndrome group of diseases. These conditions are characterized by the complete or partial blockage of one or several coronary arteries, resulting in myocardial injury or necrosis. Various medications are used in their treatment, with the most recent addition being Glycoprotein IIb/IIIa inhibitors. They work by hindering the activity of glycoprotein IIb/IIIa receptors, which, in turn, prevents the clumping of platelets...
November 2023: Curēus
#31
JOURNAL ARTICLE
Liliya E Nikitina, Pavel S Bocharov, Alexander A Ksenofontov, Elena V Antina, Ilmir R Gilfanov, Roman S Pavelyev, Olga V Ostolopovskaya, Inna V Fedyunina, Zulfiya R Azizova, Svetlana V Pestova, Evgeniy S Izmest'ev, Svetlana A Rubtsova, Sergei V Boichuk, Aigul R Galembikova, Elena A Smolyarchuk, Ilshat G Mustafin, Airat R Kayumov, Aleksandr V Samorodov
Natural monoterpenes and their derivatives are widely considered the effective ingredients for the design and production of novel biologically active compounds. In this study, by using the molecular docking technique, we examined the effects of two series of "sulfide-sulfoxide-sulfone" thioterpenoids containing different (e.g., bornane and pinane) monoterpene skeletons on the platelet's aggregation. Our data revealed that all the synthesized compounds exhibit inhibitory activities on platelet aggregation. For example, compound 1 effectively inhibited platelet activation and demonstrated direct binding with CD61 integrin, a well-known platelet GPIIb-IIIa receptor on platelets...
November 27, 2023: Biomimetics
#32
Evidence-Based Complementary And Alternative Medicine
[This retracts the article DOI: 10.1155/2021/8371996.].
2023: Evidence-based Complementary and Alternative Medicine: ECAM
#33
JOURNAL ARTICLE
Xiurong Zhu, Zhangbao Guo, Ling Tian, Guoyong Zeng, Peiyang Zhou, Zhengzhou Yuan, Hongfei Sang, Zhongming Qiu, Qingwu Yang, Youlin Wu, Jinglun Li
BACKGROUND: This study aimed to evaluate the efficacy and safety of adjuvant tirofiban in patients with acute basilar artery occlusion due to large-artery atherosclerotic (LAA) receiving endovascular therapy (EVT). METHODS: This was a non-randomized, multicenter study using data from the Endovascular Treatment for Acute BASILAR Artery Occlusion (BASILAR) registry. Patients with acute basilar artery occlusion due to LAA within 24h of symptom onset who underwent EVT were included...
December 13, 2023: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#34
REVIEW
Sem A O F Rikken, Arnoud W J van 't Hof, Jurriën M Ten Berg, Dean J Kereiakes, Barry S Coller
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000-100 000 platelets/μL), to severe (20 000 to <50 000/μL), to profound (<20 000/μL). Profound thrombocytopenia appears to occur in <1% of patients receiving their first course of therapy. Thrombocytopenia can be either acute (<24 hours) or delayed (up to ~14 days)...
December 8, 2023: Journal of the American Heart Association
#35
JOURNAL ARTICLE
Haiyan Xie, Ying Chen, Wukun Ge, Xiuping Xu, Chengjiang Liu, Zhiyong Lan, Yina Yang
BACKGROUND: Ischemic stroke is the second leading cause of death worldwide. Endovascular thrombectomy (ET) has been shown to prevent disability in a proportion of patients. The use of tirofiban in patients undergoing ET after acute stroke has resulted in improved patient function and reduced mortality to some extent. In this systematic review and meta-analysis of the current period, an overview of the most recent studies on the potential efficacy of using tirofiban to help acute stroke patients improve function and reduce mortality was provided...
January 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#36
JOURNAL ARTICLE
Zhanshu Liu, Xiaojing Huang, Xuemei Gao, Tiancong Zhang, Cui He, Ling Ding, Yuan Li
As the pathogenesis of arterial thrombosis often includes platelet adhesion and aggregation, antiplatelet agents are commonly used to prevent thromboembolic events. Here, a new microfluidic method without additional adhesion protein modification was developed to quantify the inhibitory effect of antiplatelet drugs on the adhesion and aggregation behavior of platelets on glass surfaces under physiological flow conditions. Polydimethylsiloxane (PDMS)-glass microfluidic chips were fabricated by soft photolithography...
November 23, 2023: Journal of Cardiovascular Pharmacology
#37
JOURNAL ARTICLE
Yuhui Ling, Jie Liu, Liyun Zhou, Xiuzhi Xiang, Peiming Wang
BACKGROUND AND PURPOSE: Flow diverters have emerged as viable alternatives for the retreatment of recanalized aneurysms following stent-assisted coiling embolization. In this study, we aim to present our experience of retreatment for such aneurysms using the pipeline embolization device (PED). MATERIALS AND METHODS: This case series presents a retrospective single-center analysis of patients with recanalized aneurysms who underwent retreatment using the PED between July 2019 and April 2023, subsequent to stent-assisted coiling embolization...
2023: Frontiers in Neurology
#38
JOURNAL ARTICLE
Félix Gallo-Pineda, Miriam Fernández-Gómez, Carlos Hidalgo-Barranco
BACKGROUND: Endovascular embolization of wide-necked aneurysms can be challenging. The development of intrasaccular devices like the Contour has enabled us to approach these aneurysms effectively by reducing recanalization rates and eliminating the need for dual antiplatelet therapy, which is particularly beneficial in the case of ruptured aneurysms. Although complications from using these devices are rare, it is crucial to address them properly. In this case, the authors highlight how to manage artery thrombosis caused by device protrusion during aneurysm embolization...
June 26, 2023: J Neurosurg Case Lessons
#39
JOURNAL ARTICLE
Wei-Zhen Lu, Hui-An Lin, Sen-Kuang Hou, Chyi-Huey Bai, Sheng-Feng Lin
BACKGROUND: Tirofiban is an antiplatelet treatment approved for acute coronary syndrome, but it has not been rigorously evaluated for efficacy and safety in patients with acute ischemic stroke (AIS) treated with endovascular thrombectomy (EVT). METHODS: Electronic databases were systematically searched for studies conducted from January 1, 2015, to July 31, 2021, that evaluated tirofiban administration for patients with AIS treated with EVT in comparison with control...
December 2023: Vascular Pharmacology
#40
JOURNAL ARTICLE
Bin Han, Xu Man, Jian Ding, Yuzhu Li, Xintao Tian, Xuelian Zhu, Jiang Yu, Jinping Sun
In a previously published clinical trial, we demonstrated that tirofiban was effective and safe in acute ischemic stroke (AIS) patients who did not undergo early recanalization treatments. We aimed to evaluate neuroimaging characteristics and their clinical significance to guide tirofiban treatment. In this post hoc analysis, location of infarcts (anterior circulation stroke [ACS] vs posterior circulation stroke [PCS]), degree of cerebral artery stenosis (≤ 69% vs ≥ 70% or occlusion), total infarct volume and ASPECTS were used to predict the treatment effects of tirofiban, defined as the proportions of excellent and favorable functional outcome (modified Rankin Scale (mRS) score of 0-1, 0-2) at 90 days...
November 17, 2023: Clinical and Translational Science
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
